5 Stocks to Watch: Week of 9/21/2026
We did the legwork on 5 great stocks so you can be prepared when the investing week begins…
- Century Aluminum (CENX): A top 3% analyst sees 95% upside
- Bioventus (BVS): #1 in its industry with five top grades
- IES Holdings (IESC): A fresh upgrade and nearly 40% upside ahead
- Seanergy Maritime (SHIP): Q2 earnings grew more than sevenfold
- PTC Therapeutics (PTCT): Experts believe it has 80%+ upside potential
A note from our sponsors...
The ONLY AI opportunity you should be looking at
This is the ONLY AI wealth-building opportunity you should be watching right now.
No. It's not about Nvidia, Tesla, or Meta...
It's about one overlooked company profiting off AI "digital goldmines" that are poised to experience 100x growth very soon.
This new opportunity will change the market and make investors a lot of money.
That's why it has received a $500 billion commitment from President Trump himself...
Learn more about this little-known company here >>>
1- Seanergy Maritime Holdings (NASDAQ: SHIP)
Seanergy Maritime owns and operates dry bulk ships that move commodities like iron ore and coal around the world. Right now, stronger vessel utilization, solid operating execution, and an attractive dividend yield are making this shipping stock worth a closer look.
Zen Rating: A (Strong Buy) — see full analysis
Recent Price: $18.81 — get current quote
Max 1-year forecast: $25.00
Why we're watching:
- SHIP has limited, but overall bullish, coverage among the analysts we track, with 1 Strong Buy recommendation. See all recommendations here
- For example, B. Riley Securities researcher Liam Burke (a top 11% rated analyst) recently maintained his Strong Buy recommendation with a price target nearly 33% above current levels.
- Q2 earnings demonstrated execution strength: EPS of $1.32 beat estimates by 23.5% with 633.33% year-over-year growth, while revenue of $55.69M exceeded expectations by 0.51% with 48.5% YoY growth.
- Industry ranking context: SHIP is currently the #3 highest-rated stock in the Shipping industry, which has an Industry Rating of A.
- Zen Ratings highlights: SHIP earns an overall A rating, which is equal to a Strong Buy recommendation. Stocks in this topmost tier have historically delivered nearly 30% annual returns, soundly beating the S&P.
- Component Grades: SHIP excels with As for Value, complemented by strong Bs for Growth, Momentum, and Sentiment, a profile that reflects both the company's attractive valuation and positive market dynamics in the shipping sector. See all 7 Component Grades here
A note from our sponsors...
Trump Just Changed 401(k) Rules Forever
Your 401(k) may be about to change in a way most Americans haven't heard about.
President Trump's Executive Order #14330 is pushing a major shift in how retirement plans can invest – and it has now reached the Department of Labor for approval.
Get the full story and see how your retirement could be impacted.
1- IES Holdings (NASDAQ: IESC)
IES Holdings builds the electrical and technology infrastructure that keeps data centers and other critical facilities running. Right now, booming data center demand and a major planned acquisition are giving the company an even bigger growth runway.
Zen Rating: A (Strong Buy) — see full analysis
Recent Price: $317.16— get current quote
Max 1-year forecast: $440.00
Why we're watching:
- IESC has limited, but overall bullish, coverage among the analysts we track, with 1 Strong Buy recommendation. See all recommendations here
- For example, Freedom Broker researcher Sergey Glinyanov (a top 5% rated analyst) recently upgraded his recommendation to Strong Buy with a price target suggesting the stock could see nearly 40% upside in the coming year.
- Industry ranking context: IESC is currently the #1 highest-rated stock in the Engineering & Construction industry, which has an Industry Rating of B.
- Zen Ratings highlights: IESC earns an overall A rating, equivalent to a Strong Buy recommendation. This tier represents the elite top 5% of stocks tracked, validated by a thorough 115-factor fundamental analysis framework.
- Component Grades: IESC excels with As for Financials and Sentiment, while maintaining solid B for Growth, reflecting the company's robust operational performance and positive investor outlook amid strong end-market demand. See all 7 Component Grades here
3- Bioventus (NASDAQ: BVS)
Bioventus develops medical devices and therapies that help relieve pain and treat musculoskeletal conditions. The company is drawing fresh interest after solid Q2 results and a strategic review that could unlock additional value for shareholders.
Zen Rating: A (Strong Buy) — see full analysis
Recent Price: $12.63 — get current quote
Max 1-year forecast: $19.00
Why we're watching:
- BVS has limited, but overall bullish, coverage among the analysts we track, with 2 Strong Buy and 1 Buy recommendations. See all recommendations here
- For example, Canaccord Genuity researcher Caitlin Cronin (a top 17% rated analyst) recently maintained her Strong Buy rating with a price target that suggests the stock could see nearly 50% upside in the coming year.
- Q2 came in line with expectations — adjusted EPS of $0.22 against a $0.21 consensus, up 4.8% YoY, on revenue of $153.21M that grew 3.8% but landed modestly short of estimates.
- Industry ranking context: BVS is currently the #1 highest-rated stock in the Medical Device industry, which has an Industry Rating of C.
- Zen Ratings highlights: BVS earns an overall A rating, which amounts to a Strong Buy recommendation. Stocks in this topmost tier have historically delivered nearly 30% annual returns, soundly beating the S&P.
- Component Grades: BVS earns standout grades with an A for Financials and solid Bs for Growth, Momentum, Safety, and Value, a combination that reflects strong execution and balanced fundamentals positioning the company for continued growth. See all 7 Component Grades here
4- Century Aluminum (NASDAQ: CENX)
Century Aluminum produces aluminum used across industrial and manufacturing markets in the U.S. and Iceland. Strong earnings growth and healthy profitability give it a compelling way to benefit from continued strength in aluminum demand.
Zen Rating: A (Strong Buy) — see full analysis
Recent Price: $40.75 — get current quote
Max 1-year forecast: $86.00
Why we're watching:
- CENX has limited, but overall bullish, coverage among the analysts we track, with 3 Strong Buy recommendations. See all recommendations here
- For example, B. Riley Securities researcher Lucas Pipes (a top 3% rated analyst) recently maintained his Strong Buy recommendation with a price target suggesting the stock could see nearly 111% upside in the coming year.
- Less bullish but still quite optimistic, Wells Fargo researcher Timna Tanners (a top 10% rated analyst) maintained her Strong Buy with a price target roughly 94% above current levels.
- Industry ranking context: CENX is currently the #2 highest-rated stock in the Aluminum industry, which has an Industry Rating of A.
- Zen Ratings highlights: CENX earns an overall A rating, which translates to a Strong Buy recommendation. Stocks with this rating represent the topmost tier and have historically delivered nearly 30% annual returns, significantly outperforming the S&P.
- Component Grades: CENX excels with standout As for Financials, Growth, and Value, reflecting the company's strong profitability and attractive valuation, while navigating the dynamic aluminum market with solid fundamentals. See all 7 Component Grades here
5- PTC Therapeutics (NASDAQ: PTCT)
This pharma company focused on rare genetic diseases is driving excitement with its expanding pipeline and recent data releases demonstrating broad patient benefits from its novel treatments.
Zen Rating: A (Strong Buy) — see full analysis
Recent Price: $68.00 — get current quote
Max 1-year forecast: $130.00
Why we're watching:
- PTCT has solid, bullish coverage among the analysts we track, with 7 Strong Buy and 1 Hold recommendations. See all recommendations here
- For example, Barclays researcher Eliana Merle (a top 13% rated analyst) recently maintained her Strong Buy rating with a price target that suggests the stock could see greater than 80% upside in the coming year.
- Separately, Jefferies researcher Faisal Khurshid (a top 6% rated analyst) recently upgraded their recommendation to Strong Buy, citing new patient build models suggesting revenues should continue to beat expectations.
- Industry ranking context: PTCT is currently the #13 highest-rated stocks in the Biotech industry, which has an Industry Rating of F.
- Zen Ratings highlights: PTCT earns an overall A rating, which equals a Strong Buy recommendation. This tier represents stocks that have passed a comprehensive 115-factor fundamental analysis, identifying them among the top investment opportunities in the market.
- Component Grades: PTCT earns a strong A for Growth, reflecting robust revenue expansion and promising pipeline developments, along with a solid B for Sentiment, indicating positive analyst and market reception despite the challenges facing the broader biotech sector. See all 7 Component Grades here
What to Do Next?
Want to get in touch? Email us at news@wallstreetzen.com.
Keep Reading
See All News
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.